Deborah Birx - 09 Mar 2026 Form 4 Insider Report for Armata Pharmaceuticals, Inc. (ARMP)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: ARMP
Reported as of: 09 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Mar 2026, 21:15:03 UTC
Prior SEC filing: 14 Jul 2025
Next SEC filing: 17 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Deborah Birx

Key filing fact

Deborah Birx filed Form 4 for Armata Pharmaceuticals, Inc. (ARMP) on 11 Mar 2026.

Key facts

This page summarizes Deborah Birx's Form 4 filing for Armata Pharmaceuticals, Inc. (ARMP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Mar 2026, 21:15.

Change

Previous filing in this sequence was filed on 14 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001849673 Primary reporting owner

Birx Deborah

Relationship: Chief Executive Officer, Director
Address: 5005 MCCONNELL AVENUE, LOS ANGELES
Signature: /s/ Deborah Birx
Signature date: 11 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ARMP transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value
Shares: +421,226
Change %
Price: $0.000000^*
Shares after: 421,226
Date: 09 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 421,226
Exercise price: $11.61
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Twenty-five percent (25%) of the Stock Options shall vest on March 9th of each of 2027, 2028, 2029, and 2030, in each case subject to continuous service through the applicable vesting date.